2. Inflammation/Immunology

Inflammation/Immunology (炎症/免疫)

Inflammation/Immunology

関連製品

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

製品番号 製品名 CAS 番号 純度 構造式
  • HY-151337
    Aha1/Hsp90-IN-1 2768265-58-1 98%
    Aha1/Hsp90-IN-1 (Compound 17) is an Aha1/Hsp90 complex inhibitor. Aha1/Hsp90-IN-1 disrupts Aha1/Hsp90 interactions with an IC50 of 3.32 μM. Aha1/Hsp90-IN-1 inhibits tau aggregation.
    Aha1/Hsp90-IN-1
  • HY-151450
    Cav 3.2 inhibitor 1 2878598-59-3 98%
    Cav 3.2 inhibitor 1 is a T-type calcium channel inhibitor with little binding affinity to dopamine D2 receptors. Cav 3.2 inhibitor 1 can be used for the research of somatic and visceral pain.
    Cav 3.2 inhibitor 1
  • HY-151524
    Cathepsin K inhibitor 3 1694638-70-4 98%
    Cathepsin K inhibitor 3 (compound 23) is a highly selective cathepsin K inhibitor with an IC50 value of 0.5 nM. Cathepsin K inhibitor 3 has a favorable pharmacokinetic profile and may be used in osteoarthritis (OA) disease studies.
    Cathepsin K inhibitor 3
  • HY-151535
    SARS-CoV-2 3CLpro-IN-5 2913186-57-7 98%
    SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CLpro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CLpro with an IC50 value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19).
    SARS-CoV-2 3CLpro-IN-5
  • HY-151569
    SAHA-OH 2857098-30-5 98%
    SAHA-OH is a selective HDAC6 inhibitor (IC50=23 nM), shows a 10- to 47-fold selectivity for HDAC6 compared to HDAC 1, 2, 3, and 8. SAHA-OH shows anti-inflammatory activity, and attenuates macrophage apoptosis.
    SAHA-OH
  • HY-151611
    UAMC-00050 2842774-51-8 98%
    UAMC-00050 is a potent trypsin-like serine protease inhibitor. UAMC-00050 can be used in research of dry eye syndrome and ocular inflammation.
    UAMC-00050
  • HY-151616
    sEH inhibitor-10 98%
    sEH inhibitor-10 (Compound 37) is a selective soluble epoxide hydrolase (sEH) inhibitor (IC50=0.5 μM). sEH inhibitor-10 maintains high cycloeicosatrienoic acid (EETs) levels by inhibiting sEH, thereby reducing inflammation, regulating endothelial tone, improving mitochondrial function, and reducing oxidative stress. sEH inhibitor-10 has good research potential in metabolic, renal and cardiovascular diseases.
    sEH inhibitor-10
  • HY-151617
    sEH inhibitor-11 98%
    sEH inhibitor-11 (compound 35) is a sEH inhibitor with an IC50 value of 0.3 μM. sEH inhibitor-11 can be used for the research of inflammation.
    sEH inhibitor-11
  • HY-151619
    sEH inhibitor-12 98%
    sEH inhibitor-12 (compound 34) is a sEH inhibitor with an IC50 value of 0.7 μM. sEH inhibitor-12 inhibits the 5-lipoxygenase-activating protein (FLAP)-mediated leukotriene (LT) biosynthesis with an IC50 value of 2.9 μM. sEH inhibitor-12 can be used for the research of inflammation.
    sEH inhibitor-12
  • HY-151621
    sEH inhibitor-13 98%
    sEH inhibitor-13 (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 0.4 μM.
    sEH inhibitor-13
  • HY-151805
    RGT-068A 2577171-33-4 98%
    RGT-068A is a MALT1 inhibitor with oral bioavailability. RGT-068A inhibits MALT1 activity. RGT-068A can be used for the research of autoimmune diseases.
    RGT-068A
  • HY-151806
    HadAB-IN-1 1097120-47-2 98%
    HadAB-IN-1 is a potent HadAB inhibitor. HadAB-IN-1 inhibits HadAB enzyme complexes activity with an IC50 value of 0.03 μM. HadAB-IN-1 also affects mycolic acid biosynthesis in Mycobacterium tuberculosis (Mtb). HadAB-IN-1 can be used for the research of tuberculosis (TB).
    HadAB-IN-1
  • HY-151875
    MurA-IN-3 2866186-38-9 98%
    MurA-IN-3 is a reversible pyrrolidinedione-based MurA inhibitor. MurA-IN-3 has inhibitory activity for MurA with an IC50 value of 4.5 μM. MurA-IN-3 also has antibacterial activity.
    MurA-IN-3
  • HY-151899
    A3AR modulator 1 2991693-62-8 98%
    A3AR modulator 1 (MRS8054) is an orally active A3 adenosine receptor (A3AR) (Adenosine Receptor) positive allosteric modulator (PAM). A3AR modulator 1 greatly enhances Cl-IB-MECA-stimulated [35S]GTPγS binding Emax.
    A3AR modulator 1
  • HY-151918
    Antibacterial agent 125 1274611-43-6 98.90%
    Antibacterial agent 125 is an antibacterial agent. Antibacterial agent 125 has a potent antimicrobial activity against clinically relevant Gram-positive pathogens with MIC50 values range from 0.25 - 8 μM. Antibacterial agent 125 can be used for the research of antimicrobial resistance.
    Antibacterial agent 125
  • HY-151919
    FAAH-IN-7 3037600-36-2 98%
    FAAH-IN-7 is a reversible and potent FAAH inhibitor with an IC50 value of 8.29 nM. FAAH-IN-7 suppresses oxidative stress in 1321N1 astrocytes and exhibits notable neuroprotective effect in ex vivo neuroinflammation model.
    FAAH-IN-7
  • HY-151920
    BTK-IN-17 98%
    BTK-IN-17 (compound 36R) is a selective and orally activeBTK inhibitor with an IC50 value of 13.7 nM. BTK-IN-17 decreases the expression of p-BTKY223 and p-PLCγ2Y1217. BTK-IN-17 shows anti-inflammatory effects.
    BTK-IN-17
  • HY-151921
    Anti-inflammatory agent 33 2816993-09-4 98%
    Anti-inflammatory agent 33 is a potent p38α inhibitor. Anti-inflammatory agent 33 inhibits NO production. Anti-inflammatory agent 33 inhibits LPS-induced iNOS, COX-2, p-p38α, p-MK2 protein expression. Anti-inflammatory agent 33 shows anti-inflammatory activity.
    Anti-inflammatory agent 33
  • HY-151952
    NLRP3-IN-12 98%
    NLRP3-IN-12 is a specific NLRP3 inflammasome inhibitor. NLRP3-IN-12 reduces the release of IL-1β by targeting the NLRP3 protein, with an IC50 of 0.45 μM. NLRP3-IN-12 can be used for the research of inflammatory bowel disease.
    NLRP3-IN-12
  • HY-151954
    TGFβ1-IN-2 2883813-66-7 98%
    TGFβ1-IN-2 is a diarylacylhydrazones derivative that effectively suppresses the activation and proliferation of fibroblasts. TGFβ1-IN-2 can be used for idiopathic pulmonary fibrosis (IPF) research.
    TGFβ1-IN-2
製品番号 製品名 / Synonyms Application Reactivity